IMU v CSL. Share price watch!, page-6

Just thought I should repost what I wrote on this subject one week ago as it has been lost in time and there are many newbie's here now.

There are some here that are suggesting that IMU may be the next CSL.
Well, surprisingly that may not be that far off.
IMU is now officially Australia's 2nd largest Biotech and Pharmaceutical Company with a market capital (MC) of $1.9B
This compares with Australia's 13th largest Biotech company - RAC - that has a MC of $470.5M.IMU average daily trade volume is 19,958,351 whilst RAC trades 887,708.RAC has 1 product that is possibly effective in treating specific types of 5 cancers, whereas IMU has multiple products that could virtually be effectively used in the treatment of all cancers, particularly those resistant to all other forms of treatment.
As it has multiple products predominantly viral oncolytics and B cell immunotherapies, these can be used in numerous combinations to augment the overall benefit.
IMU also has fortunately acquired some of the leading brains in oncology in the world to form it's scientific intellectual platform and has a CEO with great experience and knowledge in this field.

CSL now runs off its past merits and massive organisation accumulated through time in the industry, whereas IMU, whilst being a relative newcomer, has the greatest future potential due to it's many novel and probably effective oncology therapies.

This is a sophisticated David vs Goliath tussle and the outcome is anyone's guess.

However, as in any contest, youth usually prevails eventually.